Navigation Links
WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
Date:8/28/2012

SHANGHAI and TAIPEI, Aug. 28, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX) today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.  Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors.  This work will be completed at WuXi's biologics manufacturing facilities in China and its biologics testing facilities in the United States.  

"We are pleased that TaiMed Biologics has selected WuXi to manufacture ibalizumab for its global clinical trials because of WuXi's strong technical capabilities and high quality standards," said Edward Hu, Chief Operating Officer of WuXi PharmaTech.  "WuXi's integrated biological drug discovery, development, manufacturing and testing service platform provides our customers with a seamless solution to bring their biologics products to the market globally and in China."

"TaiMed looks forward to working with WuXi to produce clinical-trial supplies of this important new medicine for patients," said James Chang, Chief Executive Officer of TaiMed Biologics. "We are delighted to have such a skilled and reputable partner in WuXi for late-stage manufacturing as we further develop the subcutaneous formulation of our lead product, ibalizumab."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit http://www.wuxiapptec.com.

About TaiMed Biologics

TaiMed Biologics, Inc. is a publicly held Taiwanese biotechnology company with the mission to discover, develop and deliver for the global market innovative medicines that help patients prevail over serious infectious diseases. For more information, please visit http://www.taimedbiologics.com.

WuXi PharmaTech

Aaron Shi (for the media)
Tel: +86-21-5046
Email: Aaron_Shi@wuxiapptec.com

Ronald Aldridge (for investors)
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com

TaiMed Biologics

James N. Chang, PhD
Chief Executive Officer, TaiMed Biologics

Tel: 1-949-769-6543 (USA), 886-2-2655-8031 (Taiwan)
Email: jchang@taimedbiologics.com

 

 


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
2. WuXi PharmaTech Announces Second-Quarter 2012 Results
3. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
4. WuXi PharmaTech Announces First-Quarter 2012 Results
5. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
6. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
7. Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022
8. Pharmaceutical Manufacturers Attempt to Safeguard Business Continuity from Potential Threats and Disasters to Production
9. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
10. Thermal Gradient Announces Manufacture of Next Generation DNA Testing Device
11. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Cirujanos holandeses han puesto ... los médicos a compartir sus mejores prácticas por el ... Profesionales médicos de Europa, África, Asia ... la aplicación, que combina la transmisión en vivo con ... Educación   "Imagine un médico de ...
(Date:5/24/2016)... Mass. , May 24, 2016  NxStage Medical, ... technology company focused on advancing renal care, today announced ... plans to participate in the following schedule of investor ... be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, June ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... de COMBO ™ , la ... présentent des cathéters destinés à l,intervention portant ... artério-veineuse (FAV)   OrbusNeich, entreprise ... vasculaires permettant de changer la vie, a ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in the health ... of leaders in the nursing and health care industry. It also provides insight to ... Christian University. , As the nursing industry is coming out of one of ...
(Date:5/26/2016)... ... 26, 2016 , ... Despite last week’s media reports hinting at a June ... wait until March 2017 for an interest rate increase, according to Rajeev Dhawan of ... , “The Federal Open Market Committee (FOMC) dot charts are of interest to the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
(Date:5/26/2016)... ... 2016 , ... Connor Sports, through its Connor Cares initiative, will ... Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career ... all forms and levels of the game, Connor Sports has committed to a significantly ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... one that has a significant negative impact on long-term patient survival, reports a ... The results, published online this week in the Journal of Thoracic and Cardiovascular ...
Breaking Medicine News(10 mins):